Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,764.40
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.95
(
0.49%
)
Bitcoin
70,530.00
(
0.90%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 67484

Friday, 10/17/2008 3:39:37 PM

Friday, October 17, 2008 3:39:37 PM

Post# of 257262
>Will follow-on pi's (after vrtx/sgp) get to market vs placebo or do you think they need to go up against telaprevir?<

It looks like ITMN-191 will be able to go against the current SoC in phase-3 if Roche doesn’t drop the ball. The PI’s after that (including those from IDIX) will probably have to go for non-inferiority vs a newer regimen.

>Biolex just raised a bunch of committed money, so they ought to at least be able to get to market.<

I have Locteron ranked #3 (only one notch behind ITMN-191), so we’re in agreement there :- )

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now